Introduction of the Mini Review Series in Ophthalmic Research
Ying Yan,T. He,Yin Shen,Xiao Chen,B. Diao,Zhi Li,Fangchao Zhou,Y. Xing,U. Koskela,S. Kuusisto,A. Nissinen,M. Savolainen,M. Liinamaa,Hua Yan,Jing Cui,Y. Wang,Yan-ping Yu,Q. Zheng,R. Wu,Shelley Yang,Yuanping Zhang,Wensheng Li,Lin Wang,Li-li Lang,Ye Wang,Sheng Shi,Lin Liu,Dicle Hazırolan,U. Pleyer,M. Khairallah,R. Kahloun,S. B. Yahia,B. Jelliti,R. Messaoud,Satz Mengensatzproduktion,D. R. Basel
DOI: https://doi.org/10.1159/000344010
2012-12-18
Ophthalmic Research
Abstract:dates for intraocular delivery. Early approaches using intravitreal instead of parabulbar triamcinolone showed significant benefit, e.g. in uveitic cystoid macula edema [2, 4] . However, triamcinolone remained an off-label approach and side effects such as increase in intraocular pressure limit its use [5–7] . In addition, because of its short intraocular halftime, reinjections are often needed. As a consequence, more long-lasting devices were developed and legally approved. An increasing spectrum of steroid preparations including nondegradable and biodegradable devices for uveitis is currently available [8, 9] . Since repeated and long-term applications bear the risk of steroid-related complications such as increased intraocular pressure and cataract, alternative agents are currently being tested. Intravitreal injections of methotrexate, anti-VEGF, anti-TNF and sirolimus have also been applied in patients with conflicting results [10, 11] . Although intravitreal treatment has significantly reduced the incidence of adverse effects as compared to systemic application, some limitations due to their higher ocular side effects remain. As we look ahead, the future for the treatment of intraocular inflammation has never been brighter. There is great hope that there will be continued advances in the development of novel immune-modulating therapies and alternative routes of administration. Intravitreal application of specific medications might be a step in this direction. Focus on: Intravitreal Therapy in Noninfectious Uveitis
Biology